HWA
DRMA icon

HCR Wealth Advisors’s Dermata Therapeutics DRMA Stock Holding History

HCR Wealth Advisors’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-80
Closed -$19.8K – 175
2023
Q2 		$19.8K Buy
+80
New +$21.8K ﹤0.01% 176

Other funds holding DRMA

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HCR Wealth Advisors's DRMA Position: Q3 2023 in Review

HCR Wealth Advisors sold out of Dermata Therapeutics (DRMA) in Q3 2023, closing a stake of 80 shares — an estimated $19.8K sold.

HCR Wealth Advisors first reported a position in DRMA in Q2 2023 and held it in 1 quarter. The position peaked at $19.8K in Q2 2023. 6 funds tracked by Wall St. Rank hold DRMA as of Q3 2023.

  • HCR Wealth Advisors reported no remaining Dermata Therapeutics position as of Q3 2023 after selling out during the quarter.
  • HCR Wealth Advisors sold 80 Dermata Therapeutics shares in Q3 2023, an estimated $19.8K.
  • HCR Wealth Advisors first reported a position in Dermata Therapeutics in Q2 2023 and held it in 1 quarter.
  • HCR Wealth Advisors's Dermata Therapeutics position peaked at $19.8K in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q3 2023.

Based on HCR Wealth Advisors's 13F filing for Q3 2023, filed 20 Oct 2023.